Search Results - Sánchez-Campos, Noemi

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Potential Therapeutic Applications of Synthetic Conotoxin s-cal14.2b, Derived from Californiconus californicus , for Treating Type 2 Diabetes

    Potential Therapeutic Applications of Synthetic Conotoxin s-cal14.2b, Derived from Californiconus californicus , for Treating Type 2 Diabetes by Lugo-Fabres, Pavel H, Otero-Sastre, Leslie M, Bernáldez-Sarabia, Johanna, Camacho-Villegas, Tanya A, Sánchez-Campos, Noemi, Serrano-Bello, Janeth, Medina, Luis A, Muñiz-Hernández, Saé, de la Cruz, Lizbeth, Arenas, Isabel, Barajas-Martínez, Antonio, Garcia, David E, Nuñez-Garcia, Linda, González-Canudas, Jorge, Licea-Navarro, Alexei F

    Published in Biomedicines
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Chimeric Peptides from Californiconus californicus and Heterodontus francisci with Antigen-Binding Capacity: A Conotoxin Scaffold to Create Non-Natural Antibodies (NoNaBodies)

    Chimeric Peptides from Californiconus californicus and Heterodontus francisci with Antigen-Binding Capacity: A Conotoxin Scaffold to Create Non-Natural Antibodies (NoNaBodies) by Dueñas, Salvador, Escalante, Teresa, Gasperin-Bulbarela, Jahaziel, Bernáldez-Sarabia, Johanna, Cervantes-Luévano, Karla, Jiménez, Samanta, Sánchez-Campos, Noemí, Cabanillas-Bernal, Olivia, Valdovinos-Navarro, Blanca J, Álvarez-Lee, Angélica, De León-Nava, Marco A, Licea-Navarro, Alexei F

    Published in Toxins
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial

    Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial by Ventura-López, Claudia, Cervantes-Luevano, Karla, Aguirre-Sánchez, Janet S., Flores-Caballero, Juan C., Alvarez-Delgado, Carolina, Bernaldez-Sarabia, Johanna, Sánchez-Campos, Noemí, Lugo-Sánchez, Laura A., Rodríguez-Vázquez, Ileana C., Sander-Padilla, Jose G., Romero-Antonio, Yulia, Arguedas-Núñez, María M., González-Canudas, Jorge, Licea-Navarro, Alexei F.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Conotoxin Patenting Trends in Academia and Industry

    Conotoxin Patenting Trends in Academia and Industry by Sanchez-Campos, Noemi, Bernaldez-Sarabia, Johanna, Licea-Navarro, Alexei F.

    Published in Marine drugs
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2

    Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2 by Cabanillas-Bernal, Olivia, Valdovinos-Navarro, Blanca J., Cervantes-Luevano, Karla E., Sanchez-Campos, Noemi, Licea-Navarro, Alexei F.

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  6. 6
    Chimeric Peptides from ICaliforniconus californicus/I and IHeterodontus francisci/I with Antigen-Binding Capacity: A Conotoxin Scaffold to Create Non-Natural Antibodies

    Chimeric Peptides from ICaliforniconus californicus/I and IHeterodontus francisci/I with Antigen-Binding Capacity: A Conotoxin Scaffold to Create Non-Natural Antibodies by Dueñas, Salvador, Escalante, Teresa, Gasperin-Bulbarela, Jahaziel, Bernáldez-Sarabia, Johanna, Cervantes-Luévano, Karla, Jiménez, Samanta, Sánchez-Campos, Noemí, Cabanillas-Bernal, Olivia, Valdovinos-Navarro, Blanca J, Álvarez-Lee, Angélica, De León-Nava, Marco A, Licea-Navarro, Alexei F

    Published in Toxins
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF165 neutralization

    In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF165 neutralization by Millán-Gómez, Dalia, Dueñas, Salvador, Muñoz, Patricia L.A., Camacho-Villegas, Tanya, Elosua, Carolina, Cabanillas-Bernal, Olivia, Escalante, Teresa, Perona, Almudena, Abia, David, Drescher, Florian, Fournier, Pierrick G.J., Ramos, Marco A., Mares, Rosa E., Paniagua-Solis, Jorge, Mata-Gonzalez, Teresa, Gonzalez-Canudas, Jorge, Hoffman, Robert M., Licea-Navarro, Alexei, Sánchez-Campos, Noemí

    Published in Oncotarget
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF 165 neutralization

    In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF 165 neutralization by Millán-Gómez, Dalia, Dueñas, Salvador, Muñoz, Patricia L A, Camacho-Villegas, Tanya, Elosua, Carolina, Cabanillas-Bernal, Olivia, Escalante, Teresa, Perona, Almudena, Abia, David, Drescher, Florian, Fournier, Pierrick G J, Ramos, Marco A, Mares, Rosa E, Paniagua-Solis, Jorge, Mata-Gonzalez, Teresa, Gonzalez-Canudas, Jorge, Hoffman, Robert M, Licea-Navarro, Alexei, Sánchez-Campos, Noemí

    Published in Oncotarget
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: